MedImmune And National Institutes Of Health Begin Clinical Testing Of A Live, Attenuated Intranasal Vaccine Against An H5N1 Avian Influenza Virus
submited by kickingbird at Jun, 16, 2006 16:18 PM from Medical News Today
MedImmune, Inc.(Nasdaq: MEDI) announced today that the National Institutes of Health (NIH)has begun enrolling participants in a Phase 1 study of an intranasal H5N1influenza vaccine candidate based on the company´s live, attenuated vaccinetechnology. [click link for full article]
See Also:
Latest news in those days:
- US: Preliminary Testing Confirms Highly Pathogenic Avian Influenza in Queen Anne’s County in Maryland 12 hours ago
- China: Human cases of avian influenza A(H9N2) and (H10N3) reported in Hubei province, Chongqing Municipality and Guangxi Zhuang Autonomous Region 1 days ago
- US: Preliminary Testing Confirms Highly Pathogenic Avian Influenza in Caroline County in Maryland 2 days ago
- USDA Confirms Highly Pathogenic Avian Influenza in Backyard Non-Poultry Flock in Puerto Rico 2 days ago
- Scotland: Avian flu declaration near Kirriemuir, Angus on 10 January 2025 2 days ago
[Go Top] [Close Window]
